VSN-16R

N/A

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameVSN-16R
Drug Alias NameVSN-16VSN-16RVSN-16-RSPG-601
ClassificationSmall molecules
Mechanisms of ActionCalcium-activated potassium channel subunit alpha-1 activatorsCannabinoid receptor agonists
TargetsCannabinoid receptorCalcium-activated potassium channel subunit alpha-1
Therapy Area/IndicationsFragile X SyndromeMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity College London
China Registration ClassN/A

Develop Information

Active CompaniesSpinogenix IncLenire Biosciences IncUniversity College London
Inactive CompaniesCanbex Therapeutics Ltd
Active IndicationsFragile X Syndrome
Inactive IndicationsMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A